Thyme Care Series E Funding
Analysis based on 6 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026
The funding round signals strong investor confidence in value-based oncology care, potentially boosting Thyme Care's growth and market position. It may also positively influence the broader healthcare services sector, particularly companies focused on cancer care management and cost reduction.
Thyme Care, a Nashville-based oncology care company, announced a Series E financing round of over $125 million, led by Morgan Health, with participation from strategic investors including Humana, CVS Health Ventures, and several venture capital firms. The round values Thyme Care at more than $2 billion. The company also established Thyme Companies, a new parent entity, to build a portfolio of independent oncology businesses addressing barriers such as biosimilar adoption and clinical trial accrual. Thyme Care manages over $7 billion in oncology spend and serves 10.5 million people across all 50 states. The company is profitable and generates positive free cash flow. Leadership changes include co-founder Robin Shah becoming Executive Chairman of Thyme Companies, while Brad Diephuis continues as CEO of Thyme Care.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard